Continuous infusion of vancomycin less effective and safe than intermittent infusion, based on pharmacodynamic and pharmacokinetic principles

Clinical Infectious Diseases

Volumn 49, Issue 12, 2009, Pages 1964-1965

  Panday, Prachant Nannan ^a,b   Sturkenboom, Marieke ^a  

^a Dept of Clinical Pharmacy ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; VANCOMYCIN;

AREA UNDER THE CURVE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG SAFETY; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 72049108067     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648506     Document Type: Letter

References (8)

1. Rybak MJ, Lomaestro BM, Rotscahfer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-327
2. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
3. Roberts JA, Lipman J, Blot S, et al. Better outcomes through continuous infusion of timedependent antibiotics to critically ill patients? Curr Opin Crit Care 2008; 14:390-396
4. Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009; 53: 1863-1867
5. 5. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45:2460-2467 (Pubitemid 32801896)
6. Ingram PR, Lye DC, Tambyah PA, et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008;62:168-171
7. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-514
8. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006;45:755-773 (Pubitemid 44182274)